Entrada Therapeutics gets authorization to start Exon 44 skipping trial in UK

exon 44

As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization in the United Kingdom (UK) to start a Phase 1/2 trial for individuals with Duchenne amenable to exon 44 skipping. 

Part A, which is planned to start in Q2 2025, will be a multiple-ascending dose study in 24 individuals with Duchenne, with doses administered every 6 weeks.  Part B will further evaluate the optimal dose established. 

Entrada has also submitted regulatory filings to initiate trials in the US and In Europe, and those regulatory discussions are ongoing.

Press release: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-receives-authorization-united-kingdom-0

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate